Liquid Biopsy: Current Status and Future Perspective in Gastric Cancer and Helicobacter Infection.
10.7704/kjhugr.2018.18.3.150
- Author:
Eun A KANG
1
;
Young Min HAN
;
Jong Min PARK
;
In Kyung YOO
;
Sung Pyo HONG
;
Ki Baik HAHM
Author Information
1. CHA Bio Complex, CHA Cancer Prevention Research Center, Seongnam, Korea. hahmkb@cha.ac.kr
- Publication Type:Review
- Keywords:
Cell free DNA;
Circulating tumor cell;
Exosome;
Gastric cancer;
Liquid biopsy
- MeSH:
Biopsy*;
DNA;
Drug Resistance;
Exosomes;
Helicobacter Infections*;
Helicobacter pylori;
Helicobacter*;
History, Modern 1601-;
Humans;
Neoplastic Cells, Circulating;
Precision Medicine;
Recurrence;
Stomach Neoplasms*
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2018;18(3):150-156
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Precision medicine stands for 4Ps - precise, preventive, participatory, and personal; in which “precision” is important because the current modern medicine starts from “trial and error,” and “one does not fit all”. Current targeted therapies for cancer have changed treatment approaches and led the precision medicine; however, clinical use of liquid biopsy, using blood or other liquid specimens to characterize circulating tumor cells (CTC) or tumor genes instead of biopsies of tumor tissues, still awaits availability of more information regarding non-invasive cancer detection and characterization, prediction of treatment response, monitoring the disease course and relapse possibilities, identification of mechanisms of drug resistance, and newer pathogenesis. In this review, we will introduce the basic concept of CTC, circulating cell free DNA, and exosomes and their possible application for gastric cancer relevant with Helicobacter pylori infection.
